Conditions: Staphylococcal Skin Infection
Keywords: staph MRSA cSSSI
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 862
Healthy volunteers: no

Brief summary:
Study 0017 compares the safety and effectiveness of an investigational drug, telavancin, and an approved drug, vancomycin, for the treatment of complicated skin and skin structure infections.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: Telavancin intervention 2: Vancomycin
Intervention descriptions: intervention 1: Telavancin 10 mg/kg/day, IV for up to 14 days. intervention 2: Vancomycin 1 Gm IV q 12 hrs for up to 14 days.

Protocol document: